Effect of Raised End-Tidal pCo2 on Choroidal Volume
Launched by UNIVERSITY OF PITTSBURGH · Feb 16, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how changes in carbon dioxide levels in the blood might affect the volume of a part of the eye called the choroid, which is important for eye health. Researchers will use special imaging technology during eye exams performed under anesthesia to look for any connections between blood carbon dioxide levels and pressure inside the eye.
The study is open to children who are newborns up to 8 years old and are scheduled to have an eye exam under anesthesia for eye-related reasons. If a child is older than 8, not having an exam under anesthesia, or has certain medical conditions, they won’t be eligible to participate. Families can expect that their child will undergo routine eye imaging as part of their exam, and this trial aims to gather important information that could help improve eye care for children in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • any child undergoing an eye exam under anesthesia for an ophthalmologic reason.
- • children between the ages newborn to 8 years of age.
- Exclusion Criteria:
- • children who are not having an eye exam under anesthesia.
- • children with a known medical diagnosis that affect the eye to be studied
- • \* children over the age of 8 years of age.
- • \* children with altered cerebral autoregulation, increased intracranial pressure, pulmonary hypertension, or any other condition deemed appropriate by the anesthesiologist.
- • children in whom a laryngeal mask airway will not be used
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Amy Monroe, MPH, MBA
Study Director
University of Pittsburgh
Kanwal Nischal, MD,FRCOphth
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported